Sign in

    LivaNova PLC (LIVN)

    Q1 2024 Earnings Summary

    Reported on Feb 20, 2025 (Before Market Open)
    Pre-Earnings Price$55.75Last close (Apr 30, 2024)
    Post-Earnings Price$59.90Open (May 1, 2024)
    Price Change
    $4.15(+7.44%)

    What went well

    • Strong financial performance and increased 2024 guidance: LivaNova delivered a 12% revenue growth in Q1 2024 (14% excluding ACS wind down), beating expectations and leading to an increase in full-year 2024 revenue and EPS guidance. Management highlighted double-digit revenue growth in both the Cardiopulmonary and Neuromodulation segments and expressed confidence in driving sustainable above-market growth.
    • Successful launch and global rollout of the Essenz heart-lung machine: The Essenz heart-lung machine is contributing to more than 20% revenue growth in heart-lung machine revenue. The product is fully launched in the U.S. and Europe, with the rest of world rollout already starting in select markets. The company anticipates a steady increase in placements throughout the year, driven by strong customer demand and innovative features.
    • Expansion and optimization in the oxygenator business supporting future growth: LivaNova is expanding capacity at its Mirandola facility and improving manufacturing processes, which is expected to support continued strong demand and enable the company to further enhance its market position. Management expects favorable benefits from capacity expansion in the second half of 2024, contributing to growth in the oxygenator business over the next couple of years.

    What went wrong

    • The company does not expect the same level of growth in the second half of 2024 and anticipates higher spending during the remainder of the year, which may impact profitability. "We do not expect the same level of growth in the second half of 2024... we expect spending to be higher for the remainder of the year."
    • LivaNova's recent growth was partly due to temporary competitive disruptions, and with competitors potentially returning to the market, the company may face increased competition affecting its market share and growth. "We were helped in this quarter with... competitive disruptions... we are monitoring the competitive situation, never sure what the competition will do in terms of coming back into the market."
    • There is uncertainty regarding key clinical trials (RECOVER for depression and OSPREY for sleep apnea); negative or inconclusive results could lead to discontinuation or delays, impacting future growth prospects. "If the clinical data is negative, then it's a clear no-go decision... we're going to take this very slow until we see... the data."

    Q&A Summary

    1. Sleep Program Commercial Plans
      Q: What are the plans for the sleep program launch?
      A: The company expects primary endpoint data for the sleep program around year-end, aiming to file in early 2025 and potentially receive FDA approval in 2025. They will adopt a cautious approach to commercial preparations, with minimal spending in 2024, awaiting both the 7-month data and the crucial 13-month data before ramping up efforts.

    2. RECOVER Trial Impact
      Q: How will the RECOVER trial results affect strategy?
      A: The RECOVER trial results are critical and will guide strategic decisions. If the data are positive, they will work with CMS on reimbursement and determine the go/no-go decision. High-level data will be made transparent to the community by the end of the quarter, with full data available by year-end.

    3. Guidance After Q1 Beat
      Q: How does the Q1 beat impact guidance?
      A: Despite a strong Q1 beat with favorable pricing and product mix contributing to gross margin expansion, the company is taking a prudent approach to guidance, not expecting the same growth levels in the second half of 2024. They continue to invest in innovation and expect higher spending for the remainder of the year.

    4. Oxygenator Capacity Expansion
      Q: How will oxygenator capacity expansion affect growth?
      A: Capacity expansion at Mirandola is progressing well and is expected to enable growth in the second half of the year. They are monitoring the competitive landscape but are confident in capturing market share with the increased capacity.

    5. Essenz Launch and Growth
      Q: How is the Essenz launch contributing to growth?
      A: The Essenz heart-lung machine launch is driving growth through both a substantial price premium and increased unit placements. They expect a steady increase in placements throughout the year, supported by a strong funnel. The installed base is approximately 30% U.S., 20% Europe, and 50% Rest of World.

    6. Growth Sustainability and Competition
      Q: Is the growth in epilepsy and oxygenators sustainable?
      A: The company believes in sustainable above-market growth by focusing on innovation and commercial execution. In cardiopulmonary, upgrading customers to Essenz and expanding oxygenator capacity are key drivers. In neuromodulation, they aim to maintain leadership through innovation and strong physician partnerships.

    7. Chief Innovation Officer Priorities
      Q: What are the priorities for the new Chief Innovation Officer?
      A: The new Chief Innovation Officer, Ahmet, is tasked with developing top talent, improving end-to-end innovation processes, and helping assess strategic directions, including major decisions on the OSA and DTD strategies.

    8. Cost Savings from ACS Wind-down
      Q: How are cost savings from ACS wind-down impacting EPS?
      A: The company expects cost savings from the ACS wind-down to contribute approximately $0.10 to EPS, consistent with earlier guidance.

    Related Publications